The drug significantly reduced the amount of time patients spent struggling with the stiffness, slowness and tremors associated with the condition.

For people with Parkinson's disease, higher levels of physical activity were associated with slower declines in thinking and ...

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein ...

Parkinson’s disease may begin with subtle changes in movement, sleep, digestion or smell. A visible tremor is a familiar sign ...

Patients who carry a mutation in the GBA1 gene—the most common genetic risk factor for Parkinson's disease—often experience ...

As treatment options for Parkinson disease (PD) continue to expand, clinicians increasingly have to consider when patients ...

Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores ...

At least 4 hours of moderate-to-vigorous exercise weekly was associated with slower cognition and motor decline over years of ...

The drug significantly reduced the amount of time patients spent struggling with the stiffness, slowness and tremors ...

A new daily pill could help people with Parkinson’s disease live more of their life without symptoms, a trial has found.

The Takeda spinout showed that a high dose of solengepras can shorten the periods during which difficult Parkinson’s disease symptoms like involuntary movements and sleepiness.

Researchers have carried out the first single-cell analysis of mitochondrial DNA in a population of brainstem neurons that ...